1. Adamson, R. H., 1970, Carcinogenicity studies with procarbazine, in: Proceedings of the Chemotherapy Conference on Procarbazine (Matulane: NSC-77213): Development and Application ( S. K. Carter, ed.), pp. 29–33, U.S. Government Printing Office, Washington, D.C.
2. Ahmann, D. L., Hahn, R. G., and Biesel, H. F., 1972, Clinical evaluation of 5-(3,3-dimethyl-1triazeno)imidazole-4-carboxamide (NSC 45388), melphalan (NSC 8806), and hydroxyurea (NSC 32065) in the treatment of disseminated malignant melanoma, Cancer Chemother. Rep. 56: 369.
3. Ahmann, D. L., Bisel, H. F., and Hahn, R. G., 1973, Difficulties designing clinical trials as exemplified by a phase 2 drug evaluation of 5[3,3-bis(2-chloroethyl(-1-triazenol]imidazole-4-carboxamide and 1(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in patients with disseminated breast cancer, Cancer Res. 33: 1707.
4. Ahmann, D. L., Hahn, R. G., Bisel, H. F., Eagan, R. T., and Edmonson, J. H., 1975, Comparative study of methyl-CCNU (NSC 95441) with cyclophosphamide (NSC 26271) and 5-(3,3-dimethyl-1triazeno)imidazole-4-carboxamide (NSC 45388) with vincristine (NSC 67574) in patients with disseminated melanoma, Cancer Chemother. Rep. Part 1 59: 451.
5. Alberto, P., 1974, Facteurs pronostiques dans la chimiothérapie des cancer bronchiques, Schweiz. Med. Wochenschr. 104: 268.